Get started
Work

Alemtuzumab Administration in Reduced Toxicity Conditioning (RTC) Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). What Matters Most–Timing or Donor Source?

Year: 2015
Type: article
Study design: Observational Study
Abstract: The optimal timing of Alemtuzumab administration during RTC regimen is not well studied. Proximal administration may lead to more in vivo T cell depletion, decreasing GVHD but potentially increasing graft failure (GF) and delaying immune reconstitution. Intermediate administration may improve engraftment but could lead to higher rates of GVHD. We compared two centers’ experiences studying the schedule of Alemtuzumab within Busulfan/Fludarabine RTC regimen.
DOI: 10.1016/j.bbmt.2014.11.320
Authors: Monica Bhatia, Matthew Lee, Katherine Costa, Zhezhen Jin, Esra Karamehmet, James Garvin, Diane George, Andrew Kung, Christopher C. Dvorak, Biljana Horn, Prakash Satwani
Institutions: Columbia University Irving Medical Center, Columbia University, University of California, San Francisco, Johns Hopkins University, Johns Hopkins Hospital, University of San Francisco, UCSF Benioff Children's Hospital
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2321868737
FWCI:
Cites:
Cited by:
Related to: 10